Quanterix (QTRX) announced the first to market, commercial launch of two novel phospho-tau assays: p-Tau 205 and p-Tau 212, expanding its portfolio of blood-based biomarkers for Alzheimer’s disease and neurodegeneration. The announcement comes alongside Quanterix’s robust presence at the Alzheimer’s Association International Conference 2025, with more than 55 posters and presentations featuring data generated using its Simoa technology.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX: